iconiifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

JB Pharma to acquire Glenmark Pharma's entire Razel franchise

15 Dec 2022 , 01:33 PM

The transaction is expected to close within the next two weeks.
JB Chemicals & Pharmaceuticals (JB Pharma), one of India's fastest-growing pharmaceutical companies, has agreed to buy the Razel (Rousvastatin) franchise for India and Nepal from Glenmark Pharmaceuticals Ltd for Rs 314 crore.

Subject to customary closing formalities, the transaction is expected to close within the next two weeks.

JB Pharma is now a part of the 'Statin' segment, which is the largest group in cardiac therapy. Razel ranks among the top 10 brands in the Rousvastatin molecule segment in the country.

With this addition, the company has established a strong position in statins in addition to being among the leaders in hypertension and heart failure - all of which are the fastest-growing therapeutic indications in cardiology.

This acquisition will allow the company to better leverage its existing Go-To-Market model for this segment and strengthen its chronic portfolio.

At around 10.32 AM, JB Pharma was trading at Rs2,050 per piece, up by 1.26% from its previous closing of Rs2,024.45 on the BSE. The scrip opened at Rs2,055 and touched an intraday high and low of Rs2,057.25 and Rs2,036.85 respectively.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Glenmark Pharma
  • Glenmark Pharma Razel franchise
  • JB Chemicals & Pharmaceuticals
  • JB Chemicals & Pharmaceuticals Acquisition
  • JB Chemicals & Pharmaceuticals news
  • JB Chemicals & Pharmaceuticals Updates
sidebar mobile


19 Feb 2024   |   09:29 AM
Read More
Knowledge Centerplus

Logo IIFL Customer Care Number
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

Knowledge Centerplus

Follow us on


2024, IIFL Securities Ltd. All Rights Reserved

  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.